Susan Bullman receives TAMEST Mary Beth Maddox Award for breakthrough tumor microbiome research
Susan Bullman, Ph.D., associate professor of Immunology and Gastrointestinal Medical Oncology at 鶹ӳ MD Anderson Cancer Center, has received the 2027 Mary Beth Maddox Award and Lectureship from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) in recognition of her contributions to understanding how bacteria within tumors influence cancer development, treatment response and immune function...
UT MD Anderson’s Albert Koong and Katy Rezvani elected to the National Academy of Medicine
Albert Koong, M.D, Ph.D., honored for advances in radiation therapy technologies and new discoveries in cancer biology
Katy Rezvani...
Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial
Firmonertinib is an experimental therapy from ArriVent BioPharma for patients with EGFR PACC mutations
PACC mutations make up about...
AI model uses routine imaging to identify patients at risk for serious treatment-induced lung inflammation
Immunotherapy-induced lung inflammation is a potentially life-threatening condition that occurs in about 10% of lung cancer patients receiving treatment
An artificial intelligence model outperformed conventional approaches in predicting patients at elevated risk
The model demonstrated consistent performance even on external datasets that included variance in patient populations, types of CT scanners and imaging...
First-in-class therapy targets “undruggable” protein in hard-to-treat blood cancers
The MYC protein is involved in about 70% of cancers, but scientists have been unable to develop drugs that effectively block it
Scientists uncover drivers of recurrent arthritis after immunotherapy, suggesting potential biomarkers
Some patients receiving immunotherapy can develop recurrent inflammatory arthritis that often worsens in subsequent flare-ups
Researchers...
Immune cell dysfunction, not absence, defines skin cancer in immunosuppressed patients
Patients with weakened immune systems develop non-melanoma skin cancers that are more frequent, more aggressive, and more often lethal ...
Reshaping the gut microbiome can boost chemotherapy delivery to tumors
Nanoparticle-based chemotherapy is widely used but liver clearance often limits its effectiveness
The gut microbiome regulates...
Targeting a signaling pathway activated by acidic tumor environment restores treatment response to PARP inhibitors in ovarian cancer
PARP inhibitors are among the most widely used therapies for ovarian cancer, but their long-term effectiveness is limited by acquired resistance...
Epigenetic therapy shows promise against treatment-resistant AML
Next-generation epigenetic therapy showed stronger anti-leukemia activity than current standard treatments in preclinical models of acute...